AL-15469A for the Treatment of Bacterial Conjunctivitis

An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in India

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00332293

Enrollment

695

Registered

2006-06-01

Start date

2006-05-31

Completion date

2006-12-31

Last updated

2016-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial Conjunctivitis

Brief summary

The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.

Interventions

DRUGMoxifloxacin Alternative Formulation Ophthalmic Solution 0.5%

1 drop into the conjunctival sac of both eyes 3 times a day for 3 days

DRUGMoxifloxacin hydrochloride ophthalmic solution 0.5% as base

1 drop into the conjunctival sac of both eyes 3 times a day for 3 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

1 Months to No maximum

Healthy volunteers

Inclusion criteria

* signs and symptoms of bacterial conjunctivitis * Other protocol-defined inclusion criteria may apply

Exclusion criteria

* under 1 mo. age * Other protocol-defined

Design outcomes

Primary

Measure	Time frame
Clinical cure and microbiological success	—

Secondary

Measure	Time frame
Individual signs and symptoms of bacterial conjunctivitis at each visit	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026